Clinical trials
HER-2 Positive Breast Cancer clinical trials
Below are recruiting her-2 positive breast cancer clinical trials, each written for real people, not researchers. We’re tracking 253 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03643861Recruiting
Radiation after lumpectomy for certain early breast cancers
This trial tests a short, highly targeted radiation plan given in five sessions after lumpectomy for early-stage breast cancer. It may help treat the remaining breast area while aiming to limit exposure to healthy tissue.
Birmingham, AlabamaAges 18–99 - NCT03829553RecruitingPhase 3
Radiation to breast lymph nodes versus standard breast cancer care
This Phase 3 trial tests whether a shorter, more focused radiation treatment to the regional lymph nodes works as well as the current standard approach for certain breast cancers. It may help patients by potentially improving treatment efficiency while keeping cancer control effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06757621RecruitingPhase 3
Shorter Radiation for Intermediate-Risk Breast Cancer
This trial is testing a shorter course of radiation (called hypofractionated radiation) to the lymph nodes around the breast area after surgery for women with intermediate-risk breast cancer. The goal is to see if this approach works as well as standard radiation while possibly reducing side effects.
Beijing, Beijing MunicipalityAges 45 years+ - NCT07237256RecruitingPhase 3
Testing less chemo for HR+ HER2- breast cancer with ribociclib
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
AmiensAges 18 years+ - NCT07136428RecruitingPhase 1/Phase 2
Asciminib for HER2+ breast cancer that has spread to the brain
This trial tests the drug asciminib for people with HER2-positive breast cancer that has spread to the brain and is growing. It may be an option if you have already tried standard treatments like T-DXd and tucatinib.
Durham, North CarolinaAges 18 years+ - NCT05914961Recruiting
Tracking inflammation response in triple-negative breast cancer
This trial studies how a blood inflammation marker (CRP) changes after starting immunotherapy plus chemotherapy in people with triple-negative breast cancer. Results may help doctors predict who benefits from treatment and when.
TübingenAges 18 years+ - NCT04273061RecruitingPhase 2
Atezolizumab for tumors that look sensitive on DNA/RNA testing
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
Vancouver, British ColumbiaAges 18 years+ - NCT05232916RecruitingPhase 3
Vaccine for HER2-positive breast cancer after standard treatment
This trial tests a vaccine (GLSI-100) that may help prevent the return of HER2-positive breast cancer. It is given to patients who still had cancer cells after initial treatment with trastuzumab, or who had stage III disease and achieved a complete response.
Mobile, AlabamaAges 18–100 - NCT07653893Recruiting
T-DXd for breast cancer that has spread to the brain
This study is looking at how well the drug trastuzumab deruxtecan (Enhertu) works for women and men with HER2-positive breast cancer that has spread to the brain. Researchers want to see how much of the drug gets into the spinal fluid and if it helps shrink brain tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06418594RecruitingPhase 2
Drug combo for HER2-negative breast cancer brain metastasis
This trial tests a combination of two drugs (adebrelimab and apatinib) plus chemotherapy for women with HER2-negative breast cancer that has spread to the brain. It aims to see if this treatment can help shrink or control brain tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06874933RecruitingPhase 2
Chemo plus anlotinib and benmelstobart for HR+/HER2- breast cancer
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
Hangzhou, ZhejiangAges 18–75 - NCT07284836RecruitingPhase 2
Chemo directly to liver for breast cancer
This trial tests a new way to give chemotherapy directly to the liver for breast cancer that has spread only there. It's for people who have already tried two or more standard treatments.
Hangzhou, ZhejiangAges 18–70 - NCT06516289RecruitingPhase 2
Neoadjuvant treatment for BRCA-mutated HER2-negative breast cancer
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06185205RecruitingPhase 2
Accelerated high-dose radiation for early breast cancer
This trial tests a very short, high-dose radiation treatment given directly to the breast after lumpectomy. It aims to make radiation more convenient by finishing in just a few days instead of weeks, possibly with fewer side effects.
Richmond, VirginiaAges 45–79 - NCT05332561RecruitingPhase 2
Personalized treatment after surgery for early breast cancer
This Phase 2 study checks whether adding a personalized (biomarker-matched) medicine after standard chemotherapy and surgery lowers the risk of breast cancer coming back. Your study drug choice depends on tumor test results (from your tumor’s genetics and immune markers).
Heidelberg, Baden-WurttembergAges 18 years+ - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT04476485Recruiting
Predicting breast cancer recurrence after extended hormone therapy
This trial looks at factors that may predict whether hormone receptor–positive breast cancer will come back after you’ve already completed 5 years of hormone (endocrine) therapy. It may help identify who benefits most from longer treatment and follow-up.
Harbin, HeilongjiangAges 18–70 - NCT07784660Enrolling by invitationPhase 1
Imaging breast cancer with a new tracer
This trial tests a new imaging agent that may help doctors see breast cancer more clearly. The test uses a radioactive tracer that attaches to a protein on cancer cells, which could help plan your treatment.
Tomsk, Tomsk RegAges 18–80 - NCT07410676RecruitingPhase 1/Phase 2
Donor NK cells with IL-15 and pembrolizumab for advanced solid tumors
This trial tests a new type of cell therapy (natural killer cells) made from a donor, combined with low-dose IL-15 (a protein that helps these cells work) and sometimes with pembrolizumab (Keytruda), for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges Any age - NCT05866432RecruitingPhase 2
Dato-DXd for triple-negative breast cancer brain metastases
This trial studies Dato-DXd (an antibody-drug medicine) in people with triple-negative breast cancer that has spread to the brain. It aims to see how well it controls brain tumors when they are newly found or growing after other treatments.
Vienna, State of ViennaAges 18–100 - NCT04965064RecruitingPhase 2
Neratinib plus capecitabine for HER2-negative breast cancer brain mets
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
Rochester, New YorkAges 18 years+ - NCT07250386RecruitingPhase 1
CEA-targeted CAR-T therapy for advanced solid tumors
This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT04997993RecruitingPhase 1
Leflunomide for PTEN-altered or HER2-negative metastatic cancers
This Phase 1 trial studies whether leflunomide can slow or control advanced (metastatic) cancers in people whose tumors have specific PTEN changes or who have HER2-negative breast cancer. It’s primarily a safety-and-dosing study, but it may offer benefit if your cancer matches the tumor marker requirements.
New York, New YorkAges 18 years+ - NCT05386108RecruitingPhase 1/Phase 2
Test abemaciclib plus elacestrant for breast cancer brain spread
This trial studies whether the combination of abemaciclib and elacestrant can slow or shrink ER-positive, HER2-negative breast cancer that has spread to the brain. It is designed for people whose cancer has progressed despite prior hormone (endocrine) treatment.
Fullerton, CaliforniaAges 18 years+
Hear when a new HER-2 Positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her-2 positive breast cancer?
- Yes. Clin2 currently lists 253 recruiting her-2 positive breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her-2 positive breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her-2 positive breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- HR Positive/HER-2 Negative Breast Cancer
- HER2-positive Breast Cancer
- Hormone-receptor-positive Breast Cancer
- ER Positive Breast Cancer
- Estrogen-receptor-positive Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.